Carl Cook

Carl Cook has over 25 years of clinical and drug development experience with focus on design and execution of phase 1 – 4 clinical trials across many therapeutic areas, including oncology, hematology, infectious disease, cardiovascular disease, and pediatrics. Previously, Carl Cook of Clinical Operations at Black Diamond Therapeutics, and as a Senior Director at AstraZeneca, he led the delivery of the pivotal studies for gefitinib to support the NDA and JNDA submissions. Carl completed his undergraduate degree from SUNY at Buffalo and MS degree from Roswell Park C Institute/SUNY at Buffalo.